Table 1.
Patient ID |
Age (yrs) |
Gender |
PD duration (yrs) |
Main symptoms |
Daily dose (mg) |
UPDRS part III (Pre-op) |
Movement related power change (%) and electrode localisation |
Stimulation effect |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Left STN |
Right STN |
|||||||||||||||||||
OFF |
ON |
Bipoloar channel |
Beta ERD |
Gamma ERS |
Localisation |
Most %beta |
Stim setting |
Bipoloar channel |
Beta ERD |
Gamma ERS |
Localisation |
Most % beta |
Stim setting |
|||||||
1 QS |
49 |
M |
13 |
Stiffness, bradykinesia, bilateral tremor, freezing |
Levodopa 800 Apomorphine (6.5 mg/hour) Rotigotine 8 |
38 |
13 |
L1L2 |
−4.52 (*) |
17.99 (*) |
L1,L2 border MED |
L1 |
Case: + L1: - |
R1R2 |
1.15 |
33.2 (*) |
R0:inside/border/MED; R1: border/MED |
R0 |
Case: + R1: - |
UPDRS OFF Med, Stim ON/OFF: 13/38 |
2 Ox |
69 |
M |
11 |
Rigidity, bradykinesia, freezing |
Ropinirole 8 Pramipexole 0.75 Levodopa 900 |
38 |
18 |
-- |
-- |
Electrode was not in target and therefore not recorded |
R0R1 |
−4.79 |
0.92 |
R0,R1 inside only |
R1 |
None |
Stimulation was discontinued shortly after surgery due to unsatisfactory clinical effect |
|||
3 King |
65 |
F |
17 |
Rigidity, tremor |
Amantadine 400 Levodopa 600 |
55 |
49 |
L0L1 |
−5.12 (*) |
7.44 (*) |
All inside |
L1 |
Case: + L0: - |
R0R1 |
−29.03 (*) |
3.29 (*) |
All inside |
R1 |
Case: + R1: - |
Not evaluated |
4 QS |
56 |
M |
10 |
Bradykinesia, rigidity, tremor limping gait |
Levodopa 1000 Rasagiline 1 Citalopram 20 |
40 |
12 |
L1L2 |
−2.48 (*) |
37.73 (*) |
L1,L2,L3 inside; L2 dorsolat |
L2 |
Case: + L1: - |
R0R1 |
−18.92 (*) |
2.98 (*) |
R0 inside; R1 border/dorsolat |
R1 |
Case: + R0, R1 (alternating): - |
UPDRS OFF Med, Stim ON/OFF: 29/40 |
5 QS |
60 |
F |
11 |
Tremor@Left; poor coordination, bended gait |
Levodopa 600 Pramipexole 0.75 |
53 |
16 |
L1L2 |
−4.94 (*) |
6.68 (*) |
All inside; L1 dorsolat |
L1 |
Case: + L1: - |
R2R3 |
−0.049 |
2.14 |
R1 inside; R2 border |
R2 |
Case: + R1: - |
Not evaluated |
6 Kings |
65 |
M |
5 |
Rigidity, bradykinesia, motor fluctuation, tremor |
Levodopa 400 Entacapone 800 Rotigotine 8 |
41 |
29 |
L1L2 |
3.33 |
1.81 |
All inside |
None |
Case + L2: - |
R1R2 |
−7.37 (*) |
0.66 |
All inside |
R2 |
Case + R1: - |
Not evaluated |
7 QS |
56 |
M |
10 |
tremor@all four limbs |
Levodopa 600 Rotigotine 8 Selegiline 10 |
52 |
19 |
L0L1 |
−10.68 (*) |
8.42 (*) |
L2, L3 in superior STN |
L0 |
Case: + L1: - |
R0R1 |
−22.76 (*) |
14.02 (*) |
R0, R1 in STN, R2 lateral border of superior STN |
R1 |
Case + R1: - |
Relocation after recording due to side effects on speech |
8 Kings |
73 |
M |
14 |
Bradykinesia, tremor |
Rotigotine 16 Selegeline 10 Levodopa 700 |
35 |
15 |
L0L1 |
0.157 |
−0.186 |
All inside |
None |
Case: + L1: - |
R1R2 |
−4.93 (*) |
5.57 (*) |
All inside |
R1 |
Case: + R1: - |
Not evaluated |
9 Ox |
63 |
F |
14 |
Rigidity, bradykinesia |
Ropinirole 23 Levodopa 150 |
35 |
24 |
3.197 |
−1.14 |
None inside |
None |
None |
−2.59 |
7.20 |
None inside |
None |
None |
Post-op imaging show mis-location, and electrodes were relocated to GPi |
||
10 QS |
66 |
F |
16 |
Shuffle, poor balance, NO tremor |
Levodopa 600 Amantadine 200 Ropinirole 24 Rasagiline 1 |
32 |
13 |
L0L2(L1 no signal) |
4.33 |
2.95 |
L0,L1 inside |
L0 |
Case: + L1: - |
R0R1 (bipolar reduced modulation) |
−1.37 |
7.41 (*) |
R1,R2 inside |
R1 |
Case: + R1: - |
UPDRS OFF Med, Stim ON/OFF: 26/32 |
11 QS |
52 |
M |
7 |
Freezing, falls, postural instability, tremor@right side |
Levodopa 1300 Citalopram 20 Trihexyphenidyl 6 |
58 |
13 |
L1L2 (bipolar reduced modulation) |
38.77 |
13.22 |
L2 |
Case: + L1: - |
R1R2 (bipolar reduced modulation) |
−1.05 |
1.11 |
R1 |
Case: + R1: - |
Relocation after recording |
||
Mean |
61.3 |
11.3 |
43.4 |
20.1 |
(*) Indicate significant movement-related modulation in the power of the activity of the specific frequency band; Ox, Kings, QS indicate the three neurosurgical centres where the data were recorded: Ox = John Radcliffe Hospital, University of Oxford; Kings = Department of Neurosurgery, Kings College Hospital, Kings College London; QS = Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology.